# FOLFIRINOX for 2nd-line Treatment of BTC

> **NCT03778593** · PHASE2 · COMPLETED · sponsor: **Dong-A University Hospital** · enrollment: 34 (actual)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** 5-Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** Irinotecan
- **DRUG:** Oxaliplatin
- **DRUG:** 5% dextrose water

## Key facts

- **NCT ID:** NCT03778593
- **Lead sponsor:** Dong-A University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-01
- **Primary completion:** 2019-03-01
- **Final completion:** 2021-01-14
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2021-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03778593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03778593, "FOLFIRINOX for 2nd-line Treatment of BTC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03778593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*